Axtria Thought Leadership
Executive insights and perspectives on the Life Sciences industry
White Paper
COVID-19 Recession Effects On Pharmaceutical-Related Patient Health Outcomes
This white paper investigates the research framework to model the expected effects on the decline in health outcomes caused by a decrease in the quantity and quality of pharmaceuti ...
White paper
Should Pharmaceutical Incentive Compensation Plans Cap At-Risk Sales Rep Compensation?
This white paper looks at a simple but important research question – why do pharma companies have incentive compensation (IC) plans that cap their at-risk sales rep compensation? ...
White Paper
Coronavirus Pandemic Effects On Incentive Compensation
This paper focuses on coronavirus pandemic effects on IC for pharma companies in the short-term, medium-term, and long-term, while also providing prescriptive actions for sales exe ...
White Paper
Designing A Patient-Centric Commercial Strategy
This whitepaper addresses how RWE should be leveraged for informing various commercial decisions with a deeper-dive into marketing-mix analysis (MMx). ...
White Paper
How Will The Coronavirus Pandemic Affect The US Pharmaceutical Industry?
The outbreak of the coronavirus pandemic illustrates the inherent risks and uncertainties that are prevalent in the operation of complex and global business, as seen in the pharmac ...
White Paper
Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?
Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...
White Paper
One Important Lesson From Biogen’s Surprise Announcement On Hopes For An Alzheimer’s Drug
This white paper lays out the reasons for these changes and action steps executives must make to shift from the current volume-based to value/outcomes-based commercial model design ...
White Paper
Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary
This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader e ...
White Paper
AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy
This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...
